Cargando…

A novel signature based on pairwise PD‐1/PD‐L1 signaling pathway genes for predicting the overall survival in patients with hepatocellular carcinoma

Detalles Bibliográficos
Autores principales:	Zhao, Enfa, Chen, Shimin, Dang, Ying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Letter to Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140183/ https://www.ncbi.nlm.nih.gov/pubmed/34047473 http://dx.doi.org/10.1002/ctm2.431

Ejemplares similares

Development and External Validation of a Novel Immune Checkpoint–Related Gene Signature for Prediction of Overall Survival in Hepatocellular Carcinoma
por: Zhao, Enfa, et al.
Publicado: (2021)

Joint association of patients’ sex and PD‐L1 expression with overall survival benefits and tumor‐immune microenvironment in immune checkpoint inhibitors for cancers
por: Li, Anlin, et al.
Publicado: (2020)

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
por: Wu, Dawei, et al.
Publicado: (2022)

What’s the best modality for patient selection for predicting response to PD-1/PD-L1 inhibitors?
por: Bravaccini, Sara, et al.
Publicado: (2020)

PD-1/PD-L1 expression is frequent and correlated with lymphocyte density in Erdheim-Chester disease
por: Charlotte, Fréderic, et al.
Publicado: (2022)

PD‐L1/TIGIT bispecific antibody showed survival advantage in animal model
por: Mu, Songlin, et al.
Publicado: (2022)

PD-1/PD-L1 inhibitors as a hope for smokers of non-small cell lung cancer patient
por: Yu, Zhuo, et al.
Publicado: (2019)

PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials
por: Italiano, Antoine, et al.
Publicado: (2020)

Implementation of programmed death-ligand 1 (PD-L1) expression as a prognostic biomarker for patients with lung cancer
por: Li, Huijuan, et al.
Publicado: (2022)

Identification of TMB, CD8 T‐cell abundance, and homologous repair pathway mutation frequency as predictors of the benefit–toxicity ratio of anti‐PD‐1/PD‐L1 therapy
por: Long, Junyu, et al.
Publicado: (2021)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Targeting PD-1/PD-L1 interactions for cancer immunotherapy
por: Zitvogel, Laurence, et al.
Publicado: (2012)

Synchronous ground‐glass nodules showed limited response to anti‐PD‐1/PD‐L1 therapy in patients with advanced lung adenocarcinoma
por: Wu, Fengying, et al.
Publicado: (2020)

Role of GLUT-1 in the Upregulation of PD-L1 Expression After Radiotherapy and Association of PD-L1 with Favourable Overall Survival in Hypopharyngeal Cancer
por: Shen, Li-Fang, et al.
Publicado: (2020)

Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma
por: He, Gaixia, et al.
Publicado: (2015)

Pan‐cancer analysis revealing DAAM1 as a novel predictive biomarker for PD‐1/PD‐L1 blockade in clear cell renal cell carcinoma
por: Mei, Jie, et al.
Publicado: (2022)

Anti‐PD1 or anti‐PD‐L1 antibodies alone or in combination with chemotherapy first‐line treatment of advanced non‐small cell lung cancer
por: Zhang, Xuexia, et al.
Publicado: (2022)

Progress of PD-1/PD-L1 signaling in immune response to liver transplantation for hepatocellular carcinoma
por: Ju, Feng, et al.
Publicado: (2023)

A snapshot of the PD-1/PD-L1 pathway
por: Ghosh, Chinmoy, et al.
Publicado: (2021)

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
por: Garcia-Diaz, Angel, et al.
Publicado: (2017)

Human Herpesvirus and the Immune Checkpoint PD-1/PD-L1 Pathway: Disorders and Strategies for Survival
por: Murata, Takayuki
Publicado: (2021)

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019)

Response to ‘The effect of PD-L1 testing on the cost-effectiveness of immune checkpoint inhibitors’
por: Ogale, S
Publicado: (2018)

PD-L1 expression in pulmonary lymphoepithelioma-like carcinoma: is it a prognostic biomarker?
por: Li, Wen, et al.
Publicado: (2022)

The relationship between expression of PD-L1 and HIF-1α in glioma cells under hypoxia
por: Ding, Xing-chen, et al.
Publicado: (2021)

Efficacy of anti-PD1 re-treatment in patients with Hodgkin lymphoma who relapsed after anti-PD1 discontinuation
por: Manson, Guillaume, et al.
Publicado: (2020)

Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma
por: Mullane, Stephanie A., et al.
Publicado: (2016)

PD-L1 and CD4 are independent prognostic factors for overall survival in endometrial carcinomas
por: Zhang, Shuang, et al.
Publicado: (2020)

Anti-PD-L1 plus enzalutamide does not improve overall survival in prostate cancer
por: Siddiqui, Bilal A., et al.
Publicado: (2022)

Clinical outcomes and influencing factors of PD-1/PD-L1 in hepatocellular carcinoma
por: Wang, Jiting, et al.
Publicado: (2021)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

PD-L1–PD-1 Pathway in the Pathophysiology of Multiple Myeloma
por: Tamura, Hideto, et al.
Publicado: (2020)

Alterations of DNA damage response genes correlate with response and overall survival in anti‐PD‐1/PD‐L1‐treated advanced urothelial cancer
por: Joshi, Monika, et al.
Publicado: (2020)

Transcriptome-Based Co-Expression of BRD4 and PD-1/PD-L1 Predicts Poor Overall Survival in Patients With Acute Myeloid Leukemia
por: Chen, Cunte, et al.
Publicado: (2021)

Profiles of PD-1, PD-L1, PD-L2 in Gastric Cancer and Their Relation with Mutation, Immune Infiltration, and Survival
por: Liu, Jingwei, et al.
Publicado: (2020)

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
por: Tremblay-LeMay, Rosemarie, et al.
Publicado: (2018)

Immunophenotype based on inflammatory cells, PD-1/PD-L1 signalling pathway and M2 macrophages predicts survival in gastric cancer
por: Junttila, Anna, et al.
Publicado: (2020)

Clinical Value of the PD-1/PD-L1/PD-L2 Pathway in Patients Suffering from Endometriosis
por: Suszczyk, Dorota, et al.
Publicado: (2022)

The PD-1/PD-L1 Inhibitory Pathway is Altered in Primary Glomerulonephritides
por: Grywalska, Ewelina, et al.
Publicado: (2017)

The importance of the PD-1/PD-L1 pathway at the maternal-fetal interface
por: Meggyes, Matyas, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_918jkqg69bu0nu34llqcde06me